Home
News
Create
Screeners
Insights
Ishita Drugs & Indus
76.
60
-0.57
(-0.74%)
Market Cap
₹22.93 Cr
PE Ratio
29.68
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-0.74%
1M
-0.66%
6M
-1.54%
1Y
+2.82%
5Y
+159.66%
View Company Insights
Latest news about Ishita Drugs & Indus
Ishita Pharma raises stake to 1.10% in Ishita Drugs
6 hrs ago
Today
Ishita Pharmaceuticals, a related party, acquired 223 shares in Ishita Drugs & Industries via an open market transaction on June 22, 2026. This purchase increased the acquirer's stake to 1.10% from 1.09%, with the total holding reaching 32,920 shares. The disclosure was filed with BSE Limited on June 24, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Ishita Drugs FY26 net profit falls to ₹77.85 lakh
May 30, 2026
Ishita Drugs & Industries Ltd Confirms Non-Applicability of SEBI Regulation 32(1) for FY26
Apr 13, 2026
Ishita Drugs and Industries Limited Submits SEBI Compliance Certificate for Q4FY26
Apr 10, 2026
Ishita Drugs & Industries: Related Party Makes Second Share Acquisition
Feb 27, 2026
More news about Ishita Drugs & Indus
14
Feb 26
Ishita Drugs and Industries Limited Files SEBI Disclosure for Substantial Acquisition
Ishita Drugs and Industries Limited has filed a disclosure under SEBI Regulation 29(2) for substantial acquisition involving Ishita Pharmaceuticals as acquirer. The filing mentions 30,550 shares and indicates the acquirer is a related party to the target company. The disclosure, digitally signed by key personnel, demonstrates regulatory compliance for the transaction involving shares listed on BSE Limited.
07
Feb 26
Ishita Drugs Q3FY26 Results: Revenue Falls 24% to ₹313.62 Lakhs
Ishita Drugs & Industries Limited announced Q3FY26 results showing revenue decline of 24% to ₹313.62 lakhs and net profit drop of 35% to ₹15.55 lakhs. However, nine-month performance demonstrated resilience with 11.23% revenue growth and the company invested ₹165 lakhs in manufacturing facility upgrades for Revised Schedule M compliance.
30
Jan 26
Ishita Drugs & Industries Ltd Schedules Board Meeting on February 07, 2026 for Q3FY26 Financial Results
Ishita Drugs & Industries Ltd has scheduled a board meeting for February 07, 2026, to approve Q3FY26 unaudited financial results for the quarter ended December 31, 2025. The meeting complies with SEBI Regulation 29 requirements. A trading window closure is in effect from January 1, 2026, until 48 hours after results announcement, following insider trading prevention protocols.
31
Dec 25
Ishita Drugs & Industries Promoter Jagdish Agrawal Acquires Additional 254 Shares
Jagdish Agrawal, promoter of Ishita Drugs & Industries Ltd, acquired 254 equity shares worth ₹2,540 through open market transactions on December 29, 2025. His shareholding increased marginally from 4.40% to 4.41%, with total holding rising from 131,555 to 131,809 shares. The acquisition was disclosed to BSE Limited on December 30, 2025, in compliance with SEBI regulations. The company's equity share capital remains stable at ₹2.99 crores comprising 2,990,300 shares of ₹10 each.
10
Dec 25
Ishita Pharmaceuticals Increases Stake in Ishita Drugs & Industries to 1.02%
Ishita Pharmaceuticals has increased its stake in Ishita Drugs & Industries to 1.02% through an additional acquisition of 560 shares worth Rs. 10.00 each on December 08, 2025. This follows earlier investments, bringing the total holding to 30,550 shares from the previous 29,990 shares, representing continued strategic interest between the related pharmaceutical companies.
11
Nov 25
Ishita Drugs & Industries Reports Mixed Q2 Results, Progresses on Facility Upgrade
Ishita Drugs & Industries Limited reported Q2 FY2026 revenue of Rs. 806.81 lakhs, up from Rs. 692.92 lakhs in Q1. However, net profit declined to Rs. 14.33 lakhs from Rs. 30.23 lakhs. The company is upgrading its manufacturing facility to comply with Revised Schedule M regulations, with Rs. 50 lakhs spent on civil construction. The project faced delays due to extended monsoon. The company maintains a strong liquidity position with Rs. 472.68 lakhs in cash and bank balances.
Ishita Drugs & Indus
76.
60
-
0.
57
(-
0.
74
%)
1 Year Returns:
+2.82%
Industry Peers
Sun Pharmaceutical
1,874.40
(+
0.
34
%)
Divis Laboratories
6,753.50
(+
0.
10
%)
Torrent Pharmaceuticals
4,504.40
(-
0.
21
%)
Cipla
1,437.90
(+
0.
33
%)
Dr Reddys Laboratories
1,328.40
(+
2.
08
%)
Zydus Life Science
1,099.30
(-
1.
16
%)
Lupin
2,367.60
(+
0.
42
%)
Mankind Pharma
2,483.00
(-
1.
80
%)
Aurobindo Pharma
1,530.60
(-
0.
23
%)
Laurus Labs
1,454.20
(-
1.
81
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar